Concepedia

Lisa Salvatore

LS

83

Publications

6.6K

Citations

38

H-Index

1994

Active since

Affiliations

Azienda Ospedaliera Universitaria Pisana(Current)

University of Pisa

Istituto Oncologico Veneto

Istituti di Ricovero e Cura a Carattere Scientifico

Agostino Gemelli University Polyclinic

Lisa Salvatore is an author at Azienda Ospedaliera Universitaria Pisana specializing in medicine, oncology, and colorectal cancer.

ORCID

Top concepts

Publications per year

1994–2025

83

Publications

83

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 557 citations · Full text

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

Marwan Fakih, Lisa Salvatore, Taito Esaki et al. · New England Journal of Medicine · 2023 · 294 citations

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

, , +9

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

, , +9

Rows per page

1–5 of 83